Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).

NCT05011513 · clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
TERMINATED
Status
1440
Enrollment
INDUSTRY
Sponsor class

Stopped Enrollment ceased due to a very low rate of hospitalization or death observed in the standard-risk patient population

Conditions

Interventions

Sponsor

Pfizer